Join Growin Stock Community!

合一4743.TW Overview

TW StockBiotech. & Medical
(No presentation for 4743)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

合一（4743）Overall Performance

合一（4743）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

合一（4743） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

合一（4743）Key Information

合一（4743）Profile

Oneness Biotech Co., Ltd engages in the research and development of new drugs, and sale of pharmaceutical and health products in Taiwan. It operates through New Drug Research and Development, and Agricultural Products Cultivation segments. The company develops ON101, which is in Phase III clinical trials for treating chronic diabetic foot ulcers; and OB318, an anti-cancer drug that is in Phase I clinical trials. It is also developing FB704A that has completed Phase I clinical trial for the treatment of rheumatoid arthritis and systemic sclerosis; FB825, which is in Phase II clinical trial for treating atopic dermatitis, allergic diseases, and asthma; and FB918, a human monoclonal antibody, which is in pre-clinical stage for the treatment of allergic asthma. In addition, the company engages in the management of agriculture cultivation and trading business; and sale of agricultural products. The company was incorporated in 2008 and is headquartered in Taipei City, Taiwan.

合一（4743）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
26.30%
Net Margin
-1195.52%
Revenue Growth (YoY)
17.55%
Profit Growth (YoY)
-41.05%
3-Year Revenue Growth
-67.77%
3-Year Profit Growth
-76.06%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
Gross Margin
26.30%
Net Margin
-1195.52%
Revenue Growth (YoY)
17.55%
Profit Growth (YoY)
-41.05%
3-Year Revenue Growth
-67.77%
3-Year Profit Growth
-76.06%
default symbol

4743

合一

56.60D

-2.83%

(-0.03)

  • When is 4743's latest earnings report released?

    The most recent financial report for 合一 (4743) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 4743's short-term business performance and financial health. For the latest updates on 4743's earnings releases, visit this page regularly.

  • What is the operating profit of 4743?

    According to the latest financial report, 合一 (4743) reported an Operating Profit of -183.43M with an Operating Margin of -538.65% this period, representing a growth of 38.49% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is 4743's revenue growth?

    In the latest financial report, 合一 (4743) announced revenue of 34.05M, with a Year-Over-Year growth rate of 16.23%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does 4743 have?

    At the end of the period, 合一 (4743) held Total Cash and Cash Equivalents of 1.69B, accounting for 0.14 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 4743 go with three margins increasing?

    In the latest report, 合一 (4743) did not achieve the “three margins increasing” benchmark, with a gross margin of 33.41%%, operating margin of -538.65%%, and net margin of 2.45%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 4743's profit trajectory and future growth potential.

  • Is 4743's EPS continuing to grow?

    According to the past four quarterly reports, 合一 (4743)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.01. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of 4743?

    合一 (4743)'s Free Cash Flow (FCF) for the period is -57.26M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 37.75% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.